Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic significance of present atrial fibrillation on a single office electrocardiogram in patients with atrial fibrillation.

Journal of internal medicine·2020
Same author

[Long-term outcome after dialysis-dependent renal failure on the intensive care unit].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2020
Same author

[Fatigue, breathlessness and chest pain in a 31-year-old man with schizoaffective disorder].

Der Internist·2019
Same author

Heart rate variability for rapid risk stratification of emergency patients with malignant disease.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2018
Same author

Elinogrel, an orally and intravenously available ADP-receptor antagonist.

Hamostaseologie·2018
Same author

Point-of-care testing of cardiac autonomic function for risk assessment in patients with suspected acute coronary syndromes.

Clinical research in cardiology : official journal of the German Cardiac Society·2017
Same journal

Predicting deep venous thrombosis and pulmonary embolism in community patients with superficial venous thrombosis: a model development study.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Transfer of Emicizumab into Breast Milk in Postpartum Acquired Hemophilia A.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Direct oral anticoagulant use and drug-drug interactions in transplant recipients receiving calcineurin inhibitors.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Explaining recurrent thrombotic events and predicting bleeding in critically ill neonates diagnosed with umbilical central venous catheter-related portal vein thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

RNA Sequencing Indicates Distinct Platelet Transcriptomic Changes in Immune Thrombocytopenia.

Journal of thrombosis and haemostasis : JTH·2026
Same journal

Joint effect of muscle strength and physical inactivity on risk of incident venous thromboembolism: The Tromsø Study.

Journal of thrombosis and haemostasis : JTH·2026
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Platelet pharmacogenomics.

C S Zuern1, M Schwab, M Gawaz

  • 1Medizinische Klinik, Abteilung Kardiologie und Kreislauferkrankungen, University Hospital Tuebingen, Tuebingen, Germany. christine.zuern@med.uni-tuebingen.de

Journal of Thrombosis and Haemostasis : JTH
|February 5, 2010
PubMed
Summary
This summary is machine-generated.

Platelet pharmacogenomics links genetic information to drug response variability in cardiovascular patients. Genetic testing aids personalized antiplatelet therapy, but clinical benefit requires further study.

More Related Videos

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jun 16, 2026

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Platelet Biology

Background:

  • Interindividual variability in antiplatelet therapy response is significant.
  • Factors include genetics, age, gender, and co-medications.
  • Inadequate platelet inhibition leads to cardiovascular events like stent thrombosis.

Purpose of the Study:

  • To review the role of platelet pharmacogenomics in antiplatelet therapy.
  • To explore the link between genetic factors and drug response variability.
  • To discuss future directions for personalized cardiovascular treatment.

Main Methods:

  • Review of current data on pharmacogenomics in antiplatelet treatment.
  • Analysis of genetic factors influencing drug metabolism and targets.
  • Discussion of cost-effective genotyping techniques.

Main Results:

  • Genetic factors significantly contribute to antiplatelet drug response variability.
  • Pharmacogenomics offers a promising approach for individualizing therapy.
  • Affordable genotyping enables clinical application.

Conclusions:

  • Pharmacogenomics can personalize antiplatelet therapy for cardiovascular patients.
  • Integrating genetic information into treatment decisions requires further investigation.
  • Combined genetic and non-genetic risk assessment is a reasonable concept.